Patent Claims

1. Compounds of the formula I



I

in which

R^1, R^2 in each case independently of one another are aryl or Het,

aryl is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, CN, A, OA or OH,

Het is a mono- or binuclear unsaturated heterocyclic ring system which is unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, OA or OH and which contains one, two or three identical or different heteroatoms such as nitrogen, oxygen and sulfur,

A is alkyl having 1-6 C atoms,

Hal is F, Cl, Br or I,

and their physiologically acceptable salts and solvates.

2. Process for the preparation of compounds of the formula I according to Claim 1, characterized in that

a) a compound of the formula II

$$R^1\text{-}CH_2\text{-}CH_2\text{-}L \qquad II$$

in which L is Cl, Br, I or a free or reactively [sic] functionally modified OH group,
and R^1 has the meaning indicated in Claim 1,
is reacted with a compound of the formula III



III

in which R^2 and A have the meanings indicated in Claim 1,

or

b) a compound of the formula IV



IV

in which R^1 and R^2 have the meanings indicated in Claim 1,
is reacted with a compound of the formula V

R-X-A V

in which R is iodine or bromine, X is Mg
and A has the meaning indicated in Claim 1,
in a Grignard reaction,

or

c) it is liberated from one of its functional derivatives by treating with a solvolysing or hydrogenolysing agent,

or

d) a base of the formula I which is obtained is converted into one of its salts, by treating with an acid.

3. Compounds of the formula I according to Claim 1, and their physiologically acceptable salts and solvates as medicaments.

4. Compounds of the formula I according to Claim 1, and their physiologically acceptable salts and solvates as medicaments having 5-HT_{2A} receptor-antagonistic action.

5. Medicament according to Claim 4 for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, anorexia nervosa, premenstrual syndrome and/or for positively affecting compulsive behaviour (obsessive-compulsive disorder, OCD).

6. Pharmaceutical preparation, comprising at least one medicament according to Claim 5 and also, if appropriate vehicles and/or excipients and, if appropriate, other active compounds.

7. Use of compounds according to Claim 1 and/or of their physiologically acceptable salts and solvates for the production of a medicament having 5-HT_{2A} receptor-antagonistic action.

8. Use according to Claim 7 for the production of a medicament for the treatment of psychoses, schizophrenia, depression, neurological disorders,

memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, anorexia nervosa, premenstrual syndrome and/or for positively affecting compulsive behaviour (obsessive-compulsive disorder, OCD).

Sub A3 cont. 5

add A4 7